{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:17:00Z","timestamp":1780049820568,"version":"3.53.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007408","name":"Medical Center, University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) leads to right ventricular cardiomyopathy and cardiac dysfunctions where in the clinical setting, cardiac arrest is the likely cause of death, in ~70% of PAH patients. We investigated the cardiac phenotype of PAH hearts and tested the hypothesis that the insulin-like hormone, Relaxin could prevent maladaptive cardiac remodeling and protect against cardiac dysfunctions in a PAH animal model. PAH was induced in rats with sugen (20 mg\/kg), hypoxia then normoxia (3-weeks\/each); relaxin (RLX = 0, 30 or 400 \u03bcg\/kg\/day, <jats:italic>n<\/jats:italic> \u2265 6\/group) was delivered subcutaneously (6-weeks) with implanted osmotic mini-pumps. Right ventricle (RV) hemodynamics and Doppler-flow measurements were followed by cardiac isolation, optical mapping, and arrhythmia phenotype. Sugen-hypoxia (SuHx) treated rats developed PAH characterized by higher RV systolic pressures (50 \u00b1 19 vs. 22 \u00b1 5 mmHg), hypertrophy, reduced stroke volume, ventricular fibrillation (VF) (<jats:italic>n<\/jats:italic> = 6\/11) and bradycardia\/arrest (<jats:italic>n<\/jats:italic> = 5\/11); both cardiac phenotypes were suppressed with dithiothreitol (DTT = 1 mM) (<jats:italic>n<\/jats:italic> = 0\/2\/group) or RLX (low or high dose, <jats:italic>n<\/jats:italic> = 0\/6\/group). PAH hearts developed increased fibrosis that was reversed by RLX-HD, but not RLX-LD. Relaxin decreased Nrf2 and glutathione transferases but not glutathione-reductase. High-dose RLX improved pulmonary arterial compliance (measured by Doppler flow), suppressed VF even after burst-pacing, <jats:italic>n<\/jats:italic> = 2\/6). Relaxin suppressed VF and asystole through electrical remodeling and by reversing thiol oxidative stress. For the first time, we showed two cardiac phenotypes in PAH animals and their prevention by RLX. Relaxin may modulate maladaptive cardiac remodeling in PAH and protect against arrhythmia and cardiac arrest.<\/jats:p>","DOI":"10.3389\/fcvm.2021.668222","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T04:46:57Z","timestamp":1625546817000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats With Pulmonary Arterial Hypertension"],"prefix":"10.3389","volume":"8","author":[{"given":"Brian","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca R.","family":"Vanderpool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua B.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan P.","family":"Tofovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv P.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Gladwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/HYPERTENSIONAHA.114.04652","article-title":"Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect","volume":"65","author":"Bloodworth","year":"2015","journal-title":"Hypertension."},{"key":"B2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.pcad.2012.06.002","article-title":"Arrhythmias in pulmonary arterial hypertension","volume":"55","author":"Rajdev","year":"2012","journal-title":"Prog Cardiovasc Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.freeradbiomed.2012.09.013","article-title":"Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension","volume":"56","author":"Rafikova","year":"2013","journal-title":"Free Radic Biol Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","article-title":"Cardioprotective actions of relaxin","volume":"487","author":"Martin","year":"2019","journal-title":"Mol Cell Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.pupt.2005.01.003","article-title":"Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat","volume":"18","author":"Tozzi","year":"2005","journal-title":"Pulm Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1172\/JCI119099","article-title":"Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo","volume":"98","author":"Unemori","year":"1996","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1096\/fj.02-0449fje","article-title":"Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis","volume":"17","author":"Samuel","year":"2003","journal-title":"FASEB J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J Card Fail."},{"key":"B10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10741-008-9129-3","article-title":"Relaxin, a pleiotropic vasodilator for the treatment of heart failure","volume":"14","author":"Teichman","year":"2009","journal-title":"Heart Fail Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11897-010-0010-z","article-title":"Relaxin: review of biology and potential role in treating heart failure","volume":"7","author":"Teichman","year":"2010","journal-title":"Curr Heart Fail Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1161\/CIRCRESAHA.113.301646","article-title":"Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts","volume":"113","author":"Parikh","year":"2013","journal-title":"Circ Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.hrthm.2015.12.030","article-title":"Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels","volume":"13","author":"Henry","year":"2016","journal-title":"Heart Rhythm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12.17.1","DOI":"10.1002\/0471142956.cy1217s49","article-title":"Simultaneous optical mapping of intracellular free calcium and action potentials from Langendorff perfused hearts","volume":"49","author":"Salama","year":"2009","journal-title":"Curr Protoc Cytom."},{"key":"B15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1161\/01.RES.0000031801.84308.F4","article-title":"Life span of ventricular fibrillation frequencies","volume":"91","author":"Choi","year":"2002","journal-title":"Circ Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1161\/01.CIR.90.3.1469","article-title":"Optical mapping of repolarization and refractoriness from intact hearts","volume":"90","author":"Efimov","year":"1994","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.1038\/s41598-019-53867-y","article-title":"Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling","volume":"9","author":"Martin","year":"2019","journal-title":"Sci Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41580-020-0230-3","article-title":"Reactive oxygen species (ROS) as pleiotropic physiological signalling agents","volume":"21","author":"Sies","year":"2020","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1590\/0001-3765201720160348","article-title":"Thiol\/disulfide status regulates the activity of thiol-containing kinases related to energy homeostasis in rat kidney","volume":"90","author":"Rech","year":"2018","journal-title":"An Acad Bras Cienc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ceca.2016.06.001","article-title":"Reversible oxidation of vicinal-thiols motif in sarcoplasmic reticulum calcium regulatory proteins is involved in muscle fatigue mechanism","volume":"60","author":"Vazquez","year":"2016","journal-title":"Cell Calcium."},{"key":"B21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1440-1681.2007.04727.x","article-title":"Evidence for the regulation of l-type Ca2+ channels in the heart by reactive oxygen species: mechanism for mediating pathology","volume":"35","author":"Hool","year":"2008","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1016\/S0021-9258(18)90703-9","article-title":"Silver ions trigger Ca2+ release by acting at the apparent physiological release site in sarcoplasmic reticulum","volume":"259","author":"Salama","year":"1984","journal-title":"J Biol Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"21725","DOI":"10.1016\/S0021-9258(20)88246-5","article-title":"Reactive disulfides trigger Ca2+ release from sarcoplasmic reticulum via an oxidation reaction","volume":"264","author":"Zaidi","year":"1989","journal-title":"J Biol Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/BF00812073","article-title":"Critical sulfhydryls regulate calcium release from sarcoplasmic reticulum","volume":"21","author":"Abramson","year":"1989","journal-title":"J Bioenerg Biomembr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/ars.2000.2.1-5","article-title":"Molecular interaction between nitric oxide and ryanodine receptors of skeletal and cardiac sarcoplasmic reticulum","volume":"2","author":"Salama","year":"2000","journal-title":"Antioxid Redox Signal."},{"key":"B26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/00005344-200011000-00016","article-title":"Cardiac ischemia oxidizes regulatory thiols on ryanodine receptors: captopril acts as a reducing agent to improve Ca2+ uptake by ischemic sarcoplasmic reticulum","volume":"36","author":"Menshikova","year":"2000","journal-title":"J Cardiovasc Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.108.184457","article-title":"Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure","volume":"103","author":"Terentyev","year":"2008","journal-title":"Circ Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/cvr\/cvp246","article-title":"Redox modification of ryanodine receptors underlies calcium alternans in a canine model of sudden cardiac death","volume":"84","author":"Belevych","year":"2009","journal-title":"Cardiovasc Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/BC.2009.033","article-title":"Glutathione dysregulation and the etiology and progression of human diseases","volume":"390","author":"Ballatori","year":"2009","journal-title":"Biol Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.bbabio.2006.03.008","article-title":"Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate","volume":"1757","author":"Sheeran","year":"2006","journal-title":"Biochim Biophys Acta."},{"key":"B31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.phrs.2016.06.027","article-title":"Serum free thiols in chronic heart failure","volume":"111","author":"Koning","year":"2016","journal-title":"Pharmacol Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/antiox9090774","article-title":"Human relaxin-2 (serelaxin) attenuates oxidative stress in cardiac muscle cells exposed in vitro to hypoxia-Reoxygenation. Evidence for the involvement of reduced glutathione up-regulation","volume":"9","author":"Nistri","year":"2020","journal-title":"Antioxidants."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/j.ijcard.2013.11.103","article-title":"Relaxin as novel strategy in the management of atrial fibrillation: potential roles and future perspectives","volume":"171","author":"Zhao","year":"2014","journal-title":"Int J Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1096\/fj.04-3664fje","article-title":"Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model","volume":"19","author":"Perna","year":"2005","journal-title":"FASEB J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"A5566","DOI":"10.1164\/ajrccm-conference.2014.189.1_MeetingAbstracts.A5566","article-title":"Sugene 5416 dose-hypoxia-normoxia-gender interaction in angioproliferative pulmonary hypertension in rats","volume":"189","author":"Tofovic","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.668222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T04:46:59Z","timestamp":1625546819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.668222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2021.668222"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.668222","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"article-number":"668222"}}